Open AccessA Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease
Author(s) -
Harold C. Wiesenfeld,
Leslie A. Meyn,
Toni Darville,
Ingrid Macio,
Sharon L. Hillier
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa101
Subject(s) - medicine , metronidazole , ceftriaxone , tolerability , doxycycline , pelvic inflammatory disease , placebo , anaerobic bacteria , gastroenterology , regimen , mycoplasma genitalium , antibiotics , surgery , chlamydia trachomatis , adverse effect , gynecology , microbiology and biotechnology , pathology , genetics , alternative medicine , bacteria , biology
Anaerobic organisms are important pathogens in acute pelvic inflammatory disease (PID). The currently recommended PID regimen of a single dose of ceftriaxone and doxycycline for 14 days has limited anaerobic activity. The need for broader anaerobic coverage is unknown and concerns have been raised about metronidazole tolerability.